Loading stock data…
CTMX
$3.79-0.09 (-2.32%)
CytomX Therapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
CytomX Therapeutics, Inc. in the Healthcare sector is trading at $3.79. Wall Street consensus targets $13.00 (9 analysts), implying a +243.0% move over the next 12 months. The stock is currently 54% below its 52-week high of $8.21, remaining 2.8% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 21 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +243.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 21) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$3.79
Potential Downside
0%
Whystock Fair Value$3.79
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus9 analysts
Mean target$13.00+243.0%
Range$11.00 – $16.00
Fundamentals
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology bio...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$996.58M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.48
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-17.54%
Volume
Today's trading volume
2.81M
Recent News
New Forecasts: Here's What Analysts Think The Future Holds For CytomX Therapeutics, Inc. (NASDAQ:CTMX)
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shareholders will have a reason to smile today, with the analysts making...
Earnings Beat: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) investors will be delighted, with the company turning in some strong numbers...
CytomX (CTMX) Q1 2026 Earnings Transcript
2026 is off to a very exciting start, driven by our excellent clinical progress with Varseta-M in late line colorectal cancer. Varseta-M is a first-in-class EpCAM targeting antibody drug conjugate, or ADC, that was uniquely designed and enabled by our proprietary PROBODY therapeutic masking platform. EpCAM is one of the most abundant solid tumor surface antigens and CytomX's breakthrough in unlocking EpCAM as an ADC target positions Varseta-M as a company-building asset over the near and long-term.
CytomX Therapeutics Q1 Earnings Call Highlights
CytomX Therapeutics (NASDAQ:CTMX) executives highlighted progress across the company’s lead clinical programs and reviewed first-quarter 2026 financial results, emphasizing continued development momentum for its EpCAM-targeted antibody-drug conjugate Varseta-M and its masked interferon alpha-2b cand
CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue Estimates
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of +29.58% and +193.76%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?